

1 **Impact of intestinal parasitic infections on gut epithelial barrier and inflammation among**
2 **foreign-born persons living with HIV**

3 Melissa Reimer-McAtee¹, Jose Serpa², Casey McAtee³, Emma Ortega⁴, Anoma Somasunderam¹,
4 Roberto Arduino¹, Rojelio Mejia^{5,6*†} and Netanya S. Utay^{7*†}

5 † Contributed equally to this work.

6 ¹Division of Infectious Diseases, Department of Internal Medicine, University of Texas Health
7 Sciences Center, Houston, TX, USA

8 ²Division of Infectious Diseases, Department of Internal Medicine, University of Texas at Tyler,
9 Tyler, TX, USA

10 ³Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA

11 ⁴Department of Tropical Medicine and Infectious Disease, Tulane University School of Public
12 Health and Tropical Medicine, New Orleans, LA, USA

13 ⁵Department of Pediatrics: Tropical Medicine, Baylor College of Medicine, Houston, TX, USA

14 ⁶Section of Infectious Diseases, Department of Medicine, Baylor College of Medicine, Houston,
15 TX, USA

16 ⁷Division of Infectious Diseases and Geographic Medicine, Department of Internal Medicine,
17 University of Texas Southwestern Medical Center, Dallas, TX, USA

18 **Corresponding Authors:**

19 Rojelio Mejia, 1102 Bates Avenue, Suite C.0550.10 Feigin Bldg, Houston, Texas 77030, USA,

20 rmejia@bcm.edu, 832-824-0548

21 Netanya S. Utay, 5323 Harry Hines Blvd, Dallas, TX 75390, USA,

22 netanya.utay@utsouthwestern.edu, 469-291-2000

23

24 **Keywords:** HIV, parasite, parasitic infection, inflammation, sCD14, sCD163, I-FABP

25 **Running head:** Impact of intestinal parasitic infection on inflammation in PWH

26 **Word count for abstract/text:** 242/2413

27 **Number of figures/tables, supplementary info:** 1 table, 2 figures

28

29 **Abstract**

30 Systemic inflammation is a major driver of comorbidities in people with HIV (PWH). Increased
31 levels of biomarkers of enterocyte turnover, microbial translocation, and systemic inflammation
32 have been shown to predict morbidity and mortality in PWH on antiretroviral therapy (ART).
33 We conducted a prospective cohort study of foreign-born PWH with undetectable HIV RNA
34 (<20 copies/mL) with and without intestinal parasitic coinfection. Biomarkers of enterocyte
35 turnover (intestinal fatty acid binding protein [I-FABP]), microbial translocation (soluble CD14),
36 and systemic inflammation (soluble CD163) were measured. Stool parasite quantitative PCR
37 (qPCR) testing and *Strongyloides stercoralis* recombinant IgG ELISA (*Strongy* IgG) were
38 utilized to diagnose parasitic infection. Of the 52 participants, 14 (27%) tested positive for
39 infection with *Strongyloides stercoralis* by *Strongy* IgG, and 7 (16%) of the 45 participants who
40 provided stool samples tested positive for a parasitic infection (not including *Blastocystis*) by
41 stool qPCR. The median sCD14 level in PWH with (+) *Strongy* IgG was significantly higher
42 than PWH with (-) *Strongy* IgG (1.69 ug/ml versus 1.48 ug/ml, p=0.03). The median sCD163 in
43 PWH with parasitic infections by qPCR was not significantly different from sCD163 in PWH
44 negative for parasitic infections. I-FABP levels did not differ significantly between groups.
45 Participants with both HIV and intestinal parasite infections had increased levels of sCD14, a
46 marker of microbial translocation that is an independent predictor of mortality in PWH,

47 compared to PWH without parasitic infections. These findings raise concern about the long-term
48 sequelae of intestinal parasitic infections in PWH.

49

50 **Introduction**

51 Intestinal parasitic infections are often asymptomatic yet can cause chronic activation of immune
52 responses in the human host¹⁻³. Some parasites, such as *Strongyloides stercoralis*, can
53 continuously autoinfect the host for the entire lifetime if left untreated^{4,5}. Although treatable,
54 intestinal parasitic infections are underdiagnosed due to lack of testing and low sensitivity of
55 stool microscopy^{6,7}. It is known that both HIV and enteric parasitic infection cause gut damage
56 and increased microbial translocation⁸⁻¹⁰. Still, there are gaps in knowledge regarding the effects
57 of simultaneous HIV and enteric parasitic infections on enterocyte turnover, microbial
58 translocation, and systemic inflammation.

59 Parasitic infections increase CCR5⁺ CD4⁺ T-cell frequency, creating more HIV target cells in
60 persons living with HIV (PWH)^{10,11}. Parasitic infections also increase CD8⁺ T-cell activation¹.
61 Malnutrition, weight loss, chronic diarrhea, and changed immune responses caused by intestinal
62 parasitic infections may further accelerate HIV/AIDS progression¹²⁻¹⁶. Reciprocally, HIV
63 infection may impair the immune system's ability to defend against parasitic infections^{17,18}.

64 Soluble CD14 (sCD14) is a marker of microbial translocation released upon LPS stimulation¹⁹.
65 Both sCD14 and soluble CD163 (sCD163) are markers of macrophage and monocyte
66 activation¹⁹⁻²¹. Intestinal fatty acid binding protein (I-FABP) is a marker of intestinal
67 permeability and enterocyte turnover²⁰. Increased levels of each of these biomarkers have been
68 shown to predict morbidity and mortality in treated HIV infection, including cardiovascular
69 disease and neurocognitive decline¹⁹⁻²⁵.

70

71 We conducted a single-center, prospective cohort study to evaluate the impact of intestinal
72 parasitic infections on microbial translocation (sCD14), systemic inflammation (sCD163), and
73 enterocyte damage (I-FABP), and consequently, the potential for impacting morbidity and
74 mortality of PWH.

75

76 **Materials and Methods**

77 Participants were enrolled during a routine clinic visit at Thomas Street Health Center (TSHC),
78 Harris Health System, the outpatient HIV center affiliated with Baylor College of Medicine and
79 University of Texas Health Sciences Center-Houston. Inclusion criteria were as follows: age ≥ 18
80 years; foreign-born; documented HIV-1 infection; on antiretroviral therapy (ART) for >1 year;
81 plasma HIV RNA < 20 copies/ml for ≥ 6 months (1 blip of < 200 copies/ml was permitted); and
82 willingness to be treated with antiparasitic medication if indicated. Exclusion criteria were:
83 inflammatory bowel disease; malignancy of the gastrointestinal tract; major intestinal surgery in
84 the last 2 years; antiparasitic therapy in the last 1 year; pregnancy, plans to become pregnant, or
85 breastfeeding; use of antibiotics in the last 60 days; use of probiotics and prebiotics (supplements
86 and products) for more than three consecutive days within the 60 days prior to screening (yogurt
87 with live cultures allowed). Ethical approval was obtained from Baylor College of Medicine and
88 the University of Texas Health Sciences Center Institutional Review Boards. Administrative
89 approval was granted by the Harris Health System Office of Research (H-37138). Written
90 informed consent was obtained before any study procedures began.

91 Approximately 30g of stool and 20 mL of blood were collected from participants. A recombinant
92 NIE-antigen ELISA was utilized to detect *Strongyloides stercoralis* infection, including positive
93 and negative controls and a standard curve to quantify anti-*Strongyloides*-specific IgG⁷.

94

95 Multi-parallel real-time quantitative PCR (qPCR) was performed on stool to diagnose infection
96 caused by *Ancylostoma duodenale*, *Ascaris lumbricoides*, *Blastocystis* species, *Cryptosporidium*
97 *hominis/parvum*, *Cystoisospora belli*, *Entamoeba histolytica*, *Giardia intestinalis*, *Necator*
98 *americanus*, *Trichuris trichiura*, *Schistosoma spp*, and *Strongyloides stercoralis*. Multi-parallel
99 qPCR was performed as previously described²⁶ with the same species-specific primers and
100 FAM-labeled minor groove binder probes (Applied Biosystems, Foster City, CA). Samples were
101 run on an ABI ViiA7 PCR in Houston, Texas, with default parameters and 40 cycles. DNA
102 concentrations were calculated using a standard curve.

103 The biomarkers sCD14 and sCD163 were measured by Quantikine ELISA kit (R&D systems,
104 MN), and I-FABP was measured by DuoSet ELISA kit (R&D systems, MN) according to the
105 manufacturer's instructions. The plasma samples were diluted as needed by the methods
106 protocol.

107 We utilized stool quantitative PCR (qPCR) testing and *Strongyloides stercoralis* recombinant
108 IgG ELISA (*Strongy* IgG) for sensitive diagnosis of parasitic infection to compare levels of
109 sCD14, sCD163, and I-FABP to those without parasitic coinfection.

110 Results of these studies (qPCR and *Strongy* IgG) were reported to the participant's clinician, who
111 considered treatment according to the clinical condition of the patient and the local standard of
112 care, as well as discussed risks and benefits with the participant. A medical chart review
113 confirmed that each participant with positive *Strongy* IgG was treated with ivermectin. A follow-
114 up evaluation of 6 months post-treatment was scheduled for each *Strongy* IgG positive
115 participant, which consisted of a clinical evaluation and repeat blood samples for sCD14,
116 sCD163, and I-FABP level testing.

117

118 Statistical analyses were performed with R²⁷ and Prism 10.3.1 (GraphPad, Boston, MA).
119 Correlations were estimated by calculating Spearman rank correlation. Mann-Whitney u-tests
120 and Wilcoxon signed-rank tests were used to compare biomarker concentrations in parasite-
121 infected and uninfected groups, pre-and post-treatment, respectively.

122

123 **Results**

124 Fifty-two participants living with HIV born in 14 different countries were enrolled in February
125 and March of 2019. Thirty-four of the 52 (65%) were male, and the median age of participants
126 was 50 years (IQR 43-57). Participants had a median of 19 years living in the US (**Table 1**).
127 Median CD4⁺ T-cell count was 464 cells/mm³ (IQR 325-562). Plasma samples were obtained
128 from all participants; stool samples were provided by 45 of the 52 participants. Fourteen (27%)
129 participants tested positive for infection with *Strongyloides stercoralis* by *Strongy* IgG. Seven
130 (15.5%) of the 45 participants who provided stool tested positive for pathogenic parasitic
131 infection by stool qPCR: four (8.9%) with *Trichuris trichiura* (whipworm), one (2.2%) with
132 *Necator americanus* (hookworm), one participant (2.2%) with *Strongyloides stercoralis*, and one
133 (2.2%) with the protozoan infection *Entamoeba histolytica* (**Supplemental Figure 1**). Three
134 participants (7%) were coinfecting with more than one parasitic infection (either *Strongy* IgG
135 positive and stool PCR positive or stool PCR positive for two parasites). Of note, 37 (82.2%)
136 tested positive for *Blastocystis* species, which for this study was considered non-pathogenic. All
137 participants were negative for *Ancylostoma duodenale*, *Ascaris lumbricoides*, *Cryptosporidium*
138 *hominis/parvum*, *Giardia intestinalis*, and *Schistosoma spp.* Seventeen of 52 (32.7%)
139 participants were positive for either *Strongy* IgG or stool qPCR (not including *Blastocystis*


140 infection). One participant was positive for *Strongy* IgG and 3 parasites by stool qPCR- *Necator*
141 *americanus* (hookworm), *Strongyloides stercoralis*, and *Trichuris trichiura* (whipworm).
142 CD4⁺ T-cell counts were not significantly different between participants who tested positive for
143 intestinal parasitic infection and those negative for parasitic infection (431 cells/mm³ [IQR 305-
144 525] versus 492 cells/mm³ [IQR 320-655], respectively; p = 0.50). The median sCD14 level in
145 (+) *Strongy* IgG participants was significantly higher than in (-) *Strongy* IgG participants (1.69
146 µg/ml [IQR 1.51-1.88]) versus 1.48 µg/ml [IQR 1.31-1.67], p = 0.03). The median sCD14 level
147 was not significantly different between participants with or without parasitic infection (by
148 *Strongy* IgG or stool PCR), not including *Blastocystis*: 1.69 µg/ml (IQR 1.23-2.51) compared to
149 1.38 µg/ml (0.78-4.22; p = 0.07) (**Figure 1**). The median sCD163 level did not differ between
150 (+) *Strongy* IgG vs (-) *Strongy* IgG participants (674 ng/ml [IQR 551-743] versus 583 ng/ml
151 [IQR 480-760], p = 0.43). Similarly, the median sCD163 level did not differ between participants
152 with parasitic infection (not including *Blastocystis*) versus parasite-negative participants (663
153 ng/ml [IQR 573-778] versus 569 ng/ml [471-721]; p = 0.20). I-FABP levels were not
154 significantly different between (+) *Strongy* IgG and (-) *Strongy* IgG participants (832 pg/ml [IQR
155 380-1513] versus 921 pg/ml [IQR 362-2283], p = 0.98) or parasite-positive and parasite-negative
156 participants (825 pg/ml [IQR 374-1898] versus 898 pg/ml [IQR 342-2214], p = 0.76). In a
157 sensitivity analysis, participants positive and negative for parasites, including *Blastocystis*
158 species, did not have statistically significant differences in any of the three biomarker levels.

159 **Table 1. Patient Demographics**

Baseline characteristics (median [IQR] or N [%])	N=52 (%)
Male sex at birth	34 (65)
Age (years)	50 (43-57)

CD4 count (cells/mm ³)	464 (310- 615)
CD4%	28 (22- 34)
Region of origin	
North America (Mexico)	28 (54)
Central America (El Salvador, Guatemala, Honduras, Nicaragua)	11 (21)
Africa (Cameroon, Gabon, Malawi, Nigeria)	7 (14)
Caribbean (Cuba, Dominican Republic, Haiti)	3 (6)
South America (Ecuador)	2 (4)
Asia (Vietnam)	1 (2)
Time in the US (years)	19 (8-27)
Reported travel to home country in the last year	7 (13)
Time since diagnosis of HIV (years)	8 (4-14)
Absolute eosinophil count	140 (80-210)
Comorbidities	
Dyslipidemia	15 (29)
Hypertension	12 (23)
Diabetes Mellitus	7 (14)
Hepatitis C	3 (6)
Hepatitis steatosis or cirrhosis	2 (4)
Anemia	2 (4)
End-stage renal disease	1 (2)
Hepatitis B	1 (2)
Schizophrenia	1 (2)

Seizure disorder	1 (2)
Mode of transmission of HIV	
Sexual (Heterosexual)	36/49 (74)
Sexual (MSM)	12/49 (25)
Transfusion	1/49 (2)



160
 161 **Figure 1. Soluble CD14 levels in those with and without parasites.** Participants with
 162 strongyloidiasis had higher sCD14 levels ($\mu\text{g/ml}$) compared to participants without
 163 strongyloidiasis (1.69 vs. 1.48 $\mu\text{g/ml}$, respectively) (A). There was a higher sCD14 level ($\mu\text{g/ml}$)
 164 in individuals with either positive *Strongyloides* serology or positive qPCR for parasites not
 165 including *Blastocystis* (1.69 vs. 1.51 $\mu\text{g/ml}$, respectively) although not statistically significant
 166 (B).

167 **Strongyloides* positive indicates positive by *Strongyloides* IgG serology.

168 **Parasite-positive indicates positive by either *Strongyloides* IgG serology or positive by stool PCR for pathogenic
 169 parasites

170

171 Ten of the 14 participants (71%) positive by *Strongy* IgG on the initial visit were evaluated 6
172 months after parasitic infection treatment with post-treatment biomarker levels. Four of the 14
173 (29%) were lost to follow-up or unable to return because of restrictions due to the COVID-19
174 pandemic. Pre-treatment and post-treatment levels of sCD14 (1.69 vs. 1.735 $\mu\text{g/ml}$, $p = 0.829$),
175 sCD163 (673 vs. 688 ng/ml , $p = 0.752$), and I-FABP (832.1 vs. 1418 pg/ml , $p = 0.37$) were not
176 significantly different.

177 Logistical regression was used to detect predictors of *Strongy* IgG positivity. The number of
178 years living in the United States, country of origin, years since visit to home country, and
179 baseline absolute eosinophil count were not associated with test positivity.

180

181 **Discussion**

182 Both HIV and parasitic infections are known to cause intestinal damage and affect inflammatory
183 biomarkers, but the effects of HIV and parasite co-infection remain understudied. Our study
184 provides a meaningful contribution to the literature because we evaluated levels of sCD14,
185 sCD163, and I-FABP in PWH on suppressive ART in the setting of comprehensive testing for
186 parasitic infections. We found that the median sCD14 level in PWH with (+) *Strongy* IgG was
187 significantly higher than in PWH with (-) *Strongy* IgG. Given that sCD14 is an independent
188 predictor of mortality in PWH¹⁹, the increased levels of sCD14 seen in participants of our study
189 with parasitic infection raise concern about the long-term effects of enteric parasitic infection.
190 The median sCD163 and I-FABP levels did not differ significantly between PWH with and
191 without parasitic infections.

192 Our study detected a prevalence of 38% for pathogenic parasitic infection, demonstrating that
193 intestinal parasitic coinfection is common in foreign-born PWH in the US. Most of these (27%)

194 were due to infection with *Strongyloides stercoralis* detected by recombinant *Strongyloides* IgG
195 ELISA. *Strongyloides stercoralis* infection is an auto-infectious helminth^{4,5}. Thus, participants in
196 our study could have been infected years before participation in our study. The *Strongyloides*
197 adult worm releases only a few ova per day, making diagnosis difficult by stool microscopy and
198 qPCR. A positive *Strongy* IgG can be considered a test for active infection in an untreated host⁷.
199 Prior studies have shown that parasitic coinfection can negatively impact CD4 counts²⁸⁻³¹ and
200 plasma HIV RNA levels^{32,33}, but most studies have evaluated PWH, not on suppressive ART.
201 PWH in Southern Ethiopia not taking ART who were treated for *Ascaris lumbricoides* had a
202 significant increase in CD4⁺ T-cells from 469 to 551 cells/mm³ at 6 months, compared to a non-
203 significant decrease in helminth-uninfected participants³⁴. Similar results were observed in a
204 randomized, double-blind, placebo-controlled trial in ART-naive Kenyans treated for *Ascaris*
205 *lumbricoides*³⁵. PWH coinfecting with hookworm diagnosed by stool qPCR in Uganda had
206 significantly lower CD4⁺ T-cell counts, suggesting that intestinal parasitic infections could
207 contribute to the low CD4⁺ T-cell count and delayed recovery in resource-limited settings²⁸.
208 Higher plasma HIV RNA levels were observed in pregnant women with hookworm or *Trichuris*
209 *trichiura* infections³⁶. Deworming of *T. trichiura* or hookworm in an observational study
210 increased CD4⁺ T-cell counts and decreased the percentage of pregnant women on ART with
211 detectable HIV RNA levels³⁷.
212 In contrast to the studies above, a meta-analysis of randomized controlled trials of antiparasitic
213 medications or placebo in PWH with unknown parasitic infection status showed no significant
214 effect of one-time or repeated deworming on plasma HIV RNA levels or CD4⁺ T-cell count in
215 people not taking ART³⁸. A retrospective, observational study reported empiric deworming did
216 not increase CD4⁺ T-cell counts among Ugandans on ART except when restricted to women in

217 the first year of ART³⁹. A study conducted in outpatient clinics in Lilongwe, Malawi, found no
218 improvement in plasma HIV RNA levels after treatment of parasitic infection⁴⁰.

219 It is important to note that most of the studies above used stool microscopy to identify those with
220 parasitic infections. Given the low sensitivity of stool microscopy, the cohort of participants
221 identified as parasite-negative may have included several participants with unidentified parasitic
222 infections. Additionally, studies of parasitic infections in PWH *on suppressive ART* are limited.

223 With the studies above reporting the variable impact of parasitic infection on markers of HIV
224 infection, our study measured three biomarkers as an indirect evaluation of parasitic infection on
225 HIV infection in coinfecting participants. Soluble CD14 is a marker of microbial translocation
226 and LPS-bioactivity¹⁹; both sCD14 and sCD163 are markers of monocyte and macrophage
227 activation¹⁹⁻²¹. A case-control analysis of 74 PWH who died and 148 matched controls showed
228 that participants with the highest quartile of soluble CD14 (sCD14) levels had a 6-fold increased
229 risk of death compared to participants with the lowest quartile, even after adjusting for CD4⁺ T-
230 cell count and other inflammatory markers¹⁹. The mechanism of this increase in mortality is not
231 clear, but additional studies have shown an increase in cardiovascular disease and neurocognitive
232 decline in patients with elevated biomarkers²⁰⁻²³, supporting the hypothesis that prolonged
233 inflammation is harmful to the host, even if asymptomatic.

234 A key limitation of our study is the small sample size. Additionally, participants in our study left
235 their home country at variable numbers of years before enrollment in the study, had various
236 parasitic infections, and had blood, but no stool samples were available from some participants,
237 which could have contributed to sampling error. Levels of sCD163 were higher in (+) *Strongy*
238 IgG participants compared to (-) *Strongy* IgG participants and higher in participants positive by
239 stool qPCR compared to participants negative by stool qPCR, but neither reached statistical

240 significance. A study with a larger sample size would probably be needed further to study
241 sCD163 levels in PWH with intestinal parasitic infections. We did not see a decrease in any of
242 the three biomarkers measured following treatment of intestinal parasitic infection. This finding
243 may have been related to our small sample size at follow-up visits, short-term follow-up, or true
244 lack of improvement of LPS-bioactivity or change in monocyte and macrophage activation
245 following treatment. Further studies are needed to determine the impact of treatment on these
246 biomarkers. Another limitation is that we only had post-treatment biomarker results from the
247 positive participants for *Strongy* IgG.

248 It is important to note that our study benefited from highly sensitive diagnostic tests that are not
249 readily available outside the research setting. In most resource-limited clinical settings, the
250 diagnosis of intestinal parasitic infection relies on poorly sensitive stool microscopy or empiric
251 treatment is given based on clinical signs and symptoms. If additional studies show similar
252 results with elevated levels of sCD14 and sCD163, or if a study with a larger post-treatment
253 cohort shows improvement of biomarkers following treatment, then the clinical question of
254 routine empiric deworming in PWH in parasite-endemic regions should be reconsidered.
255 Given that sCD14 is an independent predictor of mortality in PWH, our study's increased levels
256 of sCD14 seen in PWH with parasitic infection raise concern about the long-term effects of
257 enteric parasitic infection. Further studies are needed to determine the clinical and virological
258 consequences of intestinal parasitic infections in PWH.

259

260 **Acknowledgments**

261 The authors wish to thank the the participants and healthcare staff of this study.

262 **Financial Support**

263 RM received funding from the Texas Developmental Center for AIDS Research (NIH

264 5P30AI161943-04).

265 **Disclosures regarding real or perceived conflicts of interest**

266 None

267 **Co-Author Contact Information**

268 1. Melissa Reimer-McAtee

269 Division of Infectious Diseases, Department of Internal Medicine, University of Texas

270 Health Sciences Center, Houston, TX, USA

271 melissa_reimer-mcatee@med.unc.edu

272 2. Jose Serpa

273 Division of Infectious Diseases, Department of Internal Medicine, University of Texas at

274 Tyler, Tyler, TX, USA

275 Jose.SerpaAlvarez@uttyler.edu

276 3. Casey McAtee

277 Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA

278 Casey.McAtee@bcm.edu

279 4. Emma Ortega

280 Department of Tropical Medicine and Infectious Disease, Tulane University School of

281 Public Health and Tropical Medicine, New Orleans, LA, USA

282 emmaortega27@gmail.com

283 5. Anoma Somasunderam

284 Division of Infectious Diseases, Department of Internal Medicine, University of Texas

285 Health Sciences Center, Houston, TX, USA

286 Anoma.Somasunderam@uth.tmc.edu

287 6. Roberto Arduino

288 Division of Infectious Diseases, Department of Internal Medicine, University of Texas

289 Health Sciences Center, Houston, TX, USA

290 Roberto.C.Arduino@uth.tmc.edu

291 7. Rojelio Mejia

292 Department of Pediatrics: Tropical Medicine, Baylor College of Medicine, Houston, TX,

293 USA

294 rmejia@bcm.edu

295 8. Netanya S. Utay

296 Division of Infectious Diseases and Geographic Medicine, Department of Internal

297 Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA

298 Netanya.Utay@UTSouthwestern.edu

299

300 **References**

301 1. Borkow G, Leng Q, Weisman Z, Stein M, Galai N, Kalinkovich A, Bentwich Z. Chronic

302 immune activation associated with intestinal helminth infections results in impaired

303 signal transduction and anergy. *The Journal of clinical investigation*. 2000;106(8):1053-

304 60. Epub 2000/10/18. doi: 10.1172/jci10182. PubMed PMID: 11032865; PMCID:

305 Pmc314342.

306 2. Ishikawa, N., P. K. Goyal, Y. R. Mahida, K. F. Li, and D. Wakelin. 1998. Early cytokine

307 responses during intestinal parasitic infections. *Immunology* 93:257-263.

- 308 3. Loukas, A., and P. Prociv. 2001. Immune responses in hookworm infections. Clin.
309 Microbiol. Rev. 14:689-703.
- 310 4. Page W, Judd JA, Bradbury RS. The Unique Life Cycle of *Strongyloides stercoralis* and
311 Implications for Public Health Action. Trop Med Infect Dis. 2018 May 25;3(2):53. doi:
312 10.3390/tropicalmed3020053. PMID: 30274449; PMCID: PMC6073624.
- 313 5. Sing A, Leitritz L, Bogner JR, Heesemann J. First-glance diagnosis of *Strongyloides*
314 *stercoralis* autoinfection by stool microscopy. J Clin Microbiol. 1999 May;37(5):1610-1.
315 doi: 10.1128/JCM.37.5.1610-1611.1999. PMID: 10203537; PMCID: PMC84850.
- 316 6. Requena-Mendez A, Chiodini P, Bisoffi Z, Buonfrate D, Gotuzzo E, et al. (2013) The
317 laboratory diagnosis and follow up of strongyloidiasis: a systematic review. *PLoS Negl*
318 *Trop Dis* 7: e2002 10.1371/journal.pntd.0002002
- 319 7. Buonfrate D, Sequi M, Mejia R, Cimino RO, Krolewiecki AJ, Albonico M, Degani M,
320 Tais S, Angheben A, Requena-Mendez A, Muñoz J, Nutman TB, Bisoffi Z. Accuracy of
321 five serologic tests for the follow up of *Strongyloides stercoralis* infection. *PLoS Negl*
322 *Trop Dis*. 2015 Feb 10;9(2):e0003491. doi: 10.1371/journal.pntd.0003491. PMID:
323 25668740; PMCID: PMC4323101.
- 324 8. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al.. Microbial
325 translocation is a cause of systemic immune activation in chronic HIV infection. *Nat*
326 *Med* (2006) 12(12):1365–71. doi: 10.1038/nm1511
- 327 9. McKay DM, Shute A, Lopes F. Helminths and intestinal barrier function. *Tissue Barriers*.
328 2017 Jan 2;5(1):e1283385. doi: 10.1080/21688370.2017.1283385. PMID: 28452686;
329 PMCID: PMC5362995.

- 330 10. George PJ, Anuradha R, Kumar NP, Kumaraswami V, Nutman TB, Babu S. Evidence of
331 microbial translocation associated with perturbations in T cell and antigen-presenting cell
332 homeostasis in hookworm infections. *PLoS neglected tropical diseases*.
333 2012;6(10):e1830. Epub 2012/10/12. doi: 10.1371/journal.pntd.0001830. PubMed PMID:
334 23056659; PMCID: Pmc3464301.
- 335 11. Sher A, Fiorentino D, Caspar P, Pearce E, Mosmann T. Production of IL-10 by CD4+ T
336 lymphocytes correlates with down-regulation of Th1 cytokine synthesis in helminth
337 infection. *Journal of immunology (Baltimore, Md : 1950)*. 1991;147(8):2713-6. Epub
338 1991/10/15. PubMed PMID: 1680917.
- 339 12. Sangare LR, Herrin BR, John-Stewart G, Walson JL. Species-specific treatment effects
340 of helminth/HIV-1 co-infection: a systematic review and meta-analysis. *Parasitology*.
341 2011;138(12):1546-58. Epub 2011/07/07. doi: 10.1017/s0031182011000357. PubMed
342 PMID: 21729353;
- 343 13. Onguru D, Liang Y, Griffith Q, Nikolajczyk B, Mwinzi P, Ganley-Leal L. Human
344 schistosomiasis is associated with endotoxemia and Toll-like receptor 2- and 4-bearing B
345 cells. *The American journal of tropical medicine and hygiene*. 2011;84(2):321-4. Epub
346 2011/02/05. doi: 10.4269/ajtmh.2011.10-0397. PubMed PMID: 21292908; PMCID:
347 Pmc3029191.
- 348 14. Aksoy E, Zouain CS, Vanhoutte F, Fontaine J, Pavelka N, Thieblemont N, Willems F,
349 Ricciardi-Castagnoli P, Goldman M, Capron M, Ryffel B, Trottein F. Double-stranded
350 RNAs from the helminth parasite *Schistosoma* activate TLR3 in dendritic cells. *The*
351 *Journal of biological chemistry*. 2005;280(1):277-83. Epub 2004/11/03. doi:
352 10.1074/jbc.M411223200. PubMed PMID: 15519998.

- 353 15. Turner JD, Jenkins GR, Hogg KG, Aynsley SA, Paveley RA, Cook PC, Coles MC,
354 Mountford AP. CD4+CD25+ regulatory cells contribute to the regulation of colonic Th2
355 granulomatous pathology caused by schistosome infection. *PLoS neglected tropical*
356 *diseases*. 2011;5(8):e1269. Epub 2011/08/23. doi: 10.1371/journal.pntd.0001269.
357 PubMed PMID: 21858239; PMCID: Pmc3153428.
- 358 16. Singh KP, Gerard HC, Hudson AP, Boros DL. Differential expression of collagen, MMP,
359 TIMP and fibrogenic-cytokine genes in the granulomatous colon of *Schistosoma*
360 *mansoni*-infected mice. *Annals of tropical medicine and parasitology*. 2006;100(7):611-
361 20. Epub 2006/09/23. doi: 10.1179/136485906x118530. PubMed PMID: 16989687.
- 362 17. Ramakrishnan K, Shenbagarathai R, Uma A, Kavitha K, Rajendran R,
363 Thirumalaikolundusubramanian P. Prevalence of intestinal parasitic infestation in
364 HIV/AIDS patients with diarrhea in Madurai City, South India. *Japanese journal of*
365 *infectious diseases*. 2007;60(4):209-10. Epub 2007/07/24. PubMed PMID: 17642535.
- 366 18. Tian LG, Wang TP, Lv S, Wang FF, Guo J, Yin XM, Cai YC, Dickey MK, Steinmann P,
367 Chen JX. HIV and intestinal parasite co-infections among a Chinese population: an
368 immunological profile. *Infectious diseases of poverty*. 2013;2(1):18. Epub 2013/08/27.
369 doi: 10.1186/2049-9957-2-18. PubMed PMID: 23971713; PMCID: Pmc3766051.
- 370 19. Sandler NG, Wand H, Roque A, Law M, Nason MC, Nixon DE, Pedersen C,
371 Ruxrungtham K, Lewin SR, Emery S, Neaton JD, Brenchley JM, Deeks SG, Sereti I,
372 Douek DC. Plasma Levels of Soluble CD14 Independently Predict Mortality in HIV
373 Infection. *J Infect Dis*. 2011. Epub 2011/01/22. doi: jiq118 [pii]10.1093/infdis/jiq118.
374 PubMed PMID: 21252259.

- 375 20. Hunt PW, Sinclair E, Rodriguez B, Shive C, Clagett B, Funderburg N, Robinson J,
376 Huang Y, Epling L, Martin JN, Deeks SG, Meinert CL, Van Natta ML, Jabs DA,
377 Lederman MM. Gut epithelial barrier dysfunction and innate immune activation predict
378 mortality in treated HIV infection. *J Infect Dis.* 2014;210(8):1228-38. doi:
379 10.1093/infdis/jiu238. PubMed PMID: 24755434; PMCID: PMC4192038.
- 380 21. Kelesidis T, Kendall MA, Yang OO, Hodis HN, Currier JS. Biomarkers of microbial
381 translocation and macrophage activation: association with progression of subclinical
382 atherosclerosis in HIV-1 infection. *J Infect Dis.* 2012;206(10):1558–1567.
383 doi:10.1093/infdis/jis545
- 384 22. Tenorio AR, Zheng Y, Bosch RJ, et al. Soluble markers of inflammation and coagulation
385 but not T-cell activation predict non-AIDS-defining morbid events during suppressive
386 antiretroviral treatment. *J Infect Dis.* 2014;210(8):1248–1259. doi:10.1093/infdis/jiu254
- 387 23. Longenecker CT, Jiang Y, Orringer CE, et al. Soluble CD14 is independently associated
388 with coronary calcification and extent of subclinical vascular disease in treated HIV
389 infection. *AIDS.* 2014;28(7):969–977. doi:10.1097/QAD.000000000000158
- 390 24. Knudsen T, Ertner G, Petersen J, et al. Plasma Soluble CD163 Level Independently
391 Predicts All-Cause Mortality in HIV-1–Infected Individuals, *The Journal of Infectious*
392 *Diseases*, Volume 214, Issue 8, 15 October 2016, Pages 1198–1204,
393 <https://doi.org/10.1093/infdis/jiw263>
- 394 25. Utay NS, Overton ET. Immune Activation and Inflammation in People With Human
395 Immunodeficiency Virus: Challenging Targets. *J Infect Dis.* 2020 Apr 27;221(10):1567-
396 1570. doi: 10.1093/infdis/jiz351. PMID: 31282534; PMCID: PMC7184903.

- 397 26. Mejia R, Vicuña Y, Broncano N, et al. A novel, multi-parallel, real-time polymerase
398 chain reaction approach for eight gastrointestinal parasites provides improved diagnostic
399 capabilities to resource-limited at-risk populations. *Am J Trop Med Hyg.*
400 2013;88(6):1041–1047. doi:10.4269/ajtmh.12-0726
- 401 27. R Core Team (2021). R: A language and environment for statistical computing. R
402 Foundation for Statistical Computing, Vienna, Austria. URL <https://www.R-project.org/>
- 403 28. Morawski BM, Yunus M, Kerukadho E, et al. Hookworm infection is associated with
404 decreased CD4+ T cell counts in HIV-infected adult Ugandans. *PLoS Negl Trop Dis.*
405 2017;11(5):e0005634. Published 2017 May 25. doi:10.1371/journal.pntd.0005634
- 406 29. Kalinkovich A, Weisman Z, Greenberg Z, Nahmias J, Eitan S, Stein M, Bentwich Z.
407 Decreased CD4 and increased CD8 counts with T cell activation is associated with
408 chronic helminth infection. *Clinical and experimental immunology.* 1998;114(3):414-21.
409 Epub 1998/12/09. PubMed PMID: 9844052; PMCID: Pmc1905129.
- 410 30. Arndt MB, John-Stewart G, Richardson BA, Singa B, van Lieshout L, Verweij JJ,
411 Sangare LR, Mbogo LW, Naulikha JM, Walson JL. Impact of helminth diagnostic test
412 performance on estimation of risk factors and outcomes in HIV-positive adults. *PloS one.*
413 2013;8(12):e81915. Epub 2013/12/11. doi: 10.1371/journal.pone.0081915. PubMed
414 PMID: 24324729; PMCID: Pmc3852669.
- 415 31. Walson JL, Stewart BT, Sangare L, Mbogo LW, Otieno PA, Piper BK, Richardson BA,
416 John-Stewart G. Prevalence and correlates of helminth co-infection in Kenyan HIV-1
417 infected adults. *PLoS neglected tropical diseases.* 2010;4(3):e644. Epub 2010/04/03. doi:
418 10.1371/journal.pntd.0000644. PubMed PMID: 20361031; PMCID: Pmc2846937.

- 419 32. Turner JD, Jenkins GR, Hogg KG, Aynsley SA, Paveley RA, Cook PC, Coles MC,
420 Mountford AP. CD4+CD25+ regulatory cells contribute to the regulation of colonic Th2
421 granulomatous pathology caused by schistosome infection. *PLoS neglected tropical*
422 *diseases*. 2011;5(8):e1269. Epub 2011/08/23. doi: 10.1371/journal.pntd.0001269.
423 PubMed PMID: 21858239; PMCID: Pmc3153428.
- 424 33. Singh KP, Gerard HC, Hudson AP, Boros DL. Differential expression of collagen, MMP,
425 TIMP and fibrogenic-cytokine genes in the granulomatous colon of *Schistosoma*
426 *mansoni*-infected mice. *Annals of tropical medicine and parasitology*. 2006;100(7):611-
427 20. Epub 2006/09/23. doi: 10.1179/136485906x118530. PubMed PMID: 16989687.
- 428 34. Abossie A, Petros B. Deworming and the immune status of HIV positive pre-
429 antiretroviral therapy individuals in Arba Minch, Chench and Gidole hospitals, Southern
430 Ethiopia. *BMC research notes*. 2015;8:483. Epub 2015/09/30. doi: 10.1186/s13104-015-
431 1461-9. PubMed PMID: 26415705; PMCID: Pmc4585997
- 432 35. Walson JL, Otieno PA, Mbuchi M, Richardson BA, Lohman-Payne B, Macharia SW,
433 Overbaugh J, Berkley J, Sanders EJ, Chung MH, John-Stewart GC. Albendazole
434 treatment of HIV-1 and helminth co-infection: a randomized, double-blind, placebo-
435 controlled trial. *AIDS (London, England)*. 2008;22(13):1601-9. Epub 2008/08/02. doi:
436 10.1097/QAD.0b013e32830a502e. PubMed PMID: 18670219; PMCID: Pmc2637615.
- 437 36. Webb EL, Kyosiimire-Lugemwa J, Kizito D, Nkurunziza P, Lule S, Muhangi L,
438 Muwanga M, Kaleebu P, Elliott AM. The effect of anthelmintic treatment during
439 pregnancy on HIV plasma viral load: results from a randomized, double-blind, placebo-
440 controlled trial in Uganda. *J Acquir Immune Defic Syndr*. 2012 Jul 1;60(3):307-13. doi:
441 10.1097/QAI.0b013e3182511e42. PMID: 22728750; PMCID: PMC3383620.

- 442 37. Ivan E, Crowther NJ, Mutimura E, Rucogoza A, Janssen S, Njunwa KK, Grobusch MP.
443 Effect of deworming on disease progression markers in HIV-1-infected pregnant women
444 on antiretroviral therapy: a longitudinal observational study from Rwanda. *Clinical*
445 *infectious diseases* : an official publication of the Infectious Diseases Society of America.
446 2015;60(1):135-42. Epub 2014/09/12. doi: 10.1093/cid/ciu715. PubMed PMID:
447 25210019.
- 448 38. Means AR, Burns P, Sinclair D, Walson JL. Anthelmintics in helminth-endemic areas:
449 effects on HIV disease progression. *Cochrane Database Syst Rev*. 2016 Apr
450 14;4(4):CD006419. doi: 10.1002/14651858.CD006419.pub4. PMID: 27075622; PMCID:
451 PMC4963621.
- 452 39. Lankowski AJ, Tsai AC, Kanyesigye M, Bwana M, Haberer JE, Wenger M, Martin JN,
453 Bangsberg DR, Hunt PW, Siedner MJ. Empiric deworming and CD4 count recovery in
454 HIV-infected Ugandans initiating antiretroviral therapy. *PLoS neglected tropical*
455 *diseases*. 2014;8(8):e3036. Epub 2014/08/08. doi: 10.1371/journal.pntd.0003036.
456 PubMed PMID: 25101890; PMCID: Pmc4125278.
- 457 40. Hosseinipour MC, Napravnik S, Joaki G, Gama S, Mbeye N, Banda B, Martinson F,
458 Hoffman I, Cohen MS. HIV and parasitic infection and the effect of treatment among
459 adult outpatients in Malawi. *J Infect Dis*. 2007 May 1;195(9):1278-82. doi:
460 10.1086/513274. Epub 2007 Mar 20. PMID: 17396996.
461